ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Co-stimulation"

  • 2022 American Transplant Congress

    T and B Cell Response to 3 Dose Covid Vaccine Series for Kidney Transplant Patients on Belatacept

    J. Christensen1, I. Yakubu2, D. Kumar1, D. Cornett3, M. A. Miller3, M. Altrich3, L. Flebbe-Rehwaldt3, R. Thompson1, G. Gupta1

    1Internal Medicine, Transplant Nephrology, VCUHealth, Richmond, VA, 2Pharmacy, VCUHealth, Richmond, VA, 3Eurofins Viracor, Lee's Summit, MO

    *Purpose: Data shows COVID vaccine response after 2 doses in patients on Belatacept immunosuppression (IS) is low, with reported rates of seroconversion (as measured by…
  • 2022 American Transplant Congress

    Long-Term Rejection Free Renal Allograft Survival with Fc-Modified Anti-cd154 Antibody Monotherapy in Nonhuman Primates

    G. Lassiter, T. Hirose, A. D’Attilio, T. Kawai

    MGH Center for Transplantation Sciences, Boston, MA

    *Purpose: Belatacept is currently the only FDA approved costimulatory blockade (CB) used as an alternative to calcineurin inhibitors in kidney transplantation. However, it has been…
  • 2022 American Transplant Congress

    TNX-1500, an Fc-Modified Anti-cd154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival

    S. Miura1, Z. Abady1, F. Pollok1, M. Ma1, K. Kinoshita1, S. Fogarty2, P. Maguire2, B. Daugherty2, S. Lederman2, R. Pierson III1

    1Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, 2Tonix Pharmaceuticals, Chatham, NJ

    *Purpose: Blockade of the CD40/CD154 T cell costimulation pathway is a promising approach to replace current clinical immunosuppression. TNX-1500 (TNX) is a novel humanized anti-CD154…
  • 2022 American Transplant Congress

    Cd137 on Host Dendritic Cells Fine-Tunes the Intesity of Donor T Cells in Systemic Alloinmmune Responses

    S. Park1, H. Cho2, B. Kwon3, J. Lee4, H. Park1, J. Park4, K. Park4, K. Yoo4

    1Department of Surgery, University of Ulsan College of Medicine, Ulsan, Korea, Republic of, 2University of Ulsan College of Medicine, Ulsan, Korea, Republic of, 3School of Biological Sciences, University of Ulsan, Ulsan, Korea, Republic of, 4Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan, Korea, Republic of

    *Purpose: CD137 is a potent costimulatory receptor for CD8+ T cells but it also regulates dendritic cells (DCs) to suppress immune responses. In this study,…
  • 2022 American Transplant Congress

    TIGIT Agonism Ameliorates Costimulation Blockade-Resistant Rejection by Increasing Quantity and Quality of Graft-Infiltrating Foxp3+ Treg

    C. R. Hartigan, D. Liu, S. Laurie, M. L. Ford

    Emory University Transplant Center, Emory University, Atlanta, GA

    *Purpose: Belatacept-based immunosuppression confers fewer off-target toxicities compared to CNI but comes at a cost of increased incidence and severity of acute rejection, potentially due…
  • 2022 American Transplant Congress

    Selective CD28 Blockade Impacts T Cell Differentiation During Hematopoietic Reconstitution Following Lymphodepletion

    J. Habib, D. Liu, R. L. Crepeau, M. E. Wagener, M. L. Ford

    Emory University, Atlanta, GA

    *Purpose: Costimulation blockade targeting the CD28 pathway provides improved long-term transplant survival without the nephrotoxicity of calcineurin inhibitors. However, treatment with the CTLA-4Ig fusion protein…
  • 2022 American Transplant Congress

    Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression

    B. Sirandas, A. Chan, M. Eiting, T. Larson, C. Truax, L. Smith

    University of Utah Health, Salt Lake City, UT

    *Purpose: The demand for kidney transplant continues to rise, and limited supply has encouraged acceptance of marginal donor organs, such as those at risk for…
  • 2022 American Transplant Congress

    Co-stimulation Patways Pd-1 (the Programmed Death 1) And Icos (the Inducible T Cell Co-stimulator) In Peripheral Mononuclear Cells Mesured By Flow Cytometry As A Possible Tool In The Follow-up And Diagnosis Of Kidney Transplant Rejection.

    M. A. Carmona-Escamilla

    Posgrado de Ciencias médicas, Universidad Nacional Autonoma de México, CDMX, Mexico

    *Purpose: Currently, the follow-up of KT in the clinic remains the creatinine levels, this is a highly specific, however, without sensitivity to determine diagnosis of…
  • 2022 American Transplant Congress

    Clinically Available Immunosuppressive Agents Prolong Pig-to-Primate Kidney Xenograft Survival

    I. J. Anwar1, Q. Gao1, I. DeLaura1, J. Yoon1, R. Baldi1, M. Youd2, K. Stiede2, K. Hall2, S. Knechtle1, J. Kwun1

    1Surgery, Duke Transplant Center, Durham, NC, 2eGenesis Inc, Cambridge, MA

    *Purpose: Most immunosuppressive regimens used in Pig-To-Primate Xenotransplantation contain anti-CD154 agents, compounds that are currently not FDA-approved. The aim of this study was to assess…
  • 2022 American Transplant Congress

    Longitudinal Characterization of Memory B Cells During Antibody Mediated Rejection Treated with Plasmapheresis, Bortezomib, and Belatacept in Heart Transplant Recipients

    F. Alkhunaizi1, M. Ellison2, V. Berrich1, M. Siegelin1, M. Szabolcs1, G. F. Sayer1, N. Uriel1, S. Restaino1, A. Chong3, A. Zeevi2, M. Habal1

    1Columbia University Medical Center, New York, NY, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3University of Chicago, Chicago, IL

    *Purpose: Donor specific antibodies (DSA) and antibody mediated rejection (AMR) continue to limit allograft longevity after heart transplant. Effective treatments are limited and often complicated…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 30
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences